4basebio (LON:4BB) Price Target Lowered to GBX 1,400 at Royal Bank Of Canada

4basebio (LON:4BB) had its price target dropped by Royal Bank Of Canada from GBX 1,600 to GBX 1,400 in a research note issued on Monday,Digital Look reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 180.00% from the stock’s previous close.

4basebio Price Performance

4basebio stock traded down GBX 25 during midday trading on Monday, reaching GBX 500. 1,239 shares of the stock traded hands, compared to its average volume of 1,727. The stock’s fifty day moving average is GBX 502.12 and its 200-day moving average is GBX 554.32. 4basebio has a 12 month low of GBX 420 and a 12 month high of GBX 1,040. The stock has a market cap of £77.43 million, a P/E ratio of -4.59 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB) last issued its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The business had revenue of GBX 169 million during the quarter. As a group, equities research analysts anticipate that 4basebio will post -3.43 EPS for the current year.

Insider Transactions at 4basebio

In related news, insider Amy Walker acquired 1,863 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of GBX 509 per share, for a total transaction of £9,482.67. 12.09% of the stock is currently owned by company insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.